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Abstract Data from clinical trials in adults, extrapolated to
predict benefits in paediatric patients, could result in fewer
or smaller trials being required to obtain a new drug licence
for paediatrics. This article outlines the place of such
extrapolation in the development of drugs for use in pae-
diatric epilepsies. Based on consensus expert opinion, a
proposal is presented for a new paradigm for the clinical
development of drugs for focal epilepsies. Phase I data
should continue to be collected in adults, and phase II and
III trials should simultaneously recruit adults and paediatric
patients aged above 2 years. Drugs would be provisionally
licensed for children subject to phase IV collection of
neurodevelopmental safety data in this age group. A single
programme of trials would suffice to license the drug for
use as either adjunctive therapy or monotherapy. Patients,
clinicians and sponsors would all benefit from this new
structure through cost reduction and earlier access to novel
treatments. Further work is needed to elicit the views of
patients, their parents and guardians as appropriate, regu-
latory authorities and bodies such as the National Institute
for Health and Care Excellence (UK).
Key Points
Based on consensus expert opinion, we propose a
new paradigm for the clinical development of drugs
for focal epilepsies.
In this new paradigm phase II and III trials should
simultaneously recruit adults and paediatric patients
aged above 2 years and drugs would be provisionally
licensed for children subject to phase IV collection
of neurodevelopmental safety data.
Patients, clinicians and sponsors would all benefit
from this new structure through cost reduction and
earlier access to novel treatments.
1 Introduction
The European Medicines Agency (EMA) defines extrapo-
lation as ‘‘…extending information and conclusions avail-
able from studies in one or more subgroups of the patient
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population (source population)… to make inferences for
another subgroup of the population (target population)…’’
[1, 2]. There are several examples of how this definition
can be applied. Using the terminology of Dunne et al. [3],
extrapolation can range from complete (no additional data
needed in the target population) to partial (supporting data
needed) to none. Extrapolation can be used to streamline
drug development. Avoiding unnecessary studies in popu-
lations whose response to therapy is well understood
enables sponsors to focus research on patient groups about
which least is known. This paper considers how the
extrapolation of adult efficacy and safety data can be used
to streamline the development of drugs for use in paediatric
epilepsies.
Off-label prescribing in paediatrics is prevalent in the
USA [4] and EU [5]. In routine clinical practice, informal
extrapolation from adult data increases the confidence of
doctors and families regarding off-label prescribing in
children. When developing new medicines, it is reasonable
practice to extrapolate from adult data to predict the clin-
ical benefits of a new medicine in paediatrics such that
smaller trials may suffice to demonstrate efficacy in this
age group. However, extrapolations only have value if
robust assumptions on similarity hold when applied to the
adult and paediatric populations. The US Food and Drug
Administration (FDA) [6] and International Council for
Harmonisation of Technical Requirements for Pharma-
ceuticals for Human Use (ICH) E11 [7] guidelines outline
an algorithmic approach for determining which data are
needed to support paediatric licensing of a medicine
depending on whether it is reasonable to assume that dis-
ease progression, drug pharmacology, and pharmacoki-
netic/pharmacodynamic relationships are consistent across
adults and paediatric patients. An alternative framework
has recently been proposed which stipulates that emerging
and cumulative data in the target population should be used
to confirm extrapolation assumptions [1, 2].
In the context of epilepsy research, it is not always
possible to predict clinical benefits in paediatric patients
using adult data due to disparities in the different types
(syndromes) of epilepsy and their specific natural histories.
The acceptability of extrapolation will depend on several
factors, including age, seizure type and epilepsy syndrome,
treatment regimen and the individual antiepileptic drug
(AED). Whilst there is broad agreement that efficacy in
adults with focal epilepsies can be extrapolated to paedi-
atric patients with focal epilepsies, there is disagreement
about the boundary of certainty, with different expert
groups supporting extrapolation down to the ages of either
2 [8] or 4 years [9]. The FDA has recently suggested that
complete extrapolation of efficacy from adult to paediatric
patients aged 4 years and older with partial-onset seizures
is acceptable [10]. This is a major development, and one
that is consistent with our view, but the potential of
extrapolation goes much further.
This paper explores these issues and provides recom-
mendations on the role of extrapolation in drug develop-
ment for epilepsy and identifies opportunities to improve
current practice. It reflects work conducted within a project
funded by the National Institute for Health Research (UK)
on extrapolation approaches in paediatric trials.
2 Considerations
2.1 Are Paediatric Patients Just Small Adults?
In the case of common focal epilepsies, the answer to the
question ‘‘are paediatric patients just small adults?’’ may
well be yes. The aetiology of extra-temporal focal epilepsy
in both adults and children is predominated by vascular
lesions, trauma and, most frequently, cortical dysplasias.
Dysplasias are present from birth and while the time to
seizure onset may vary widely, the underlying pathology is
the same, which suggests that this is likely to reflect a
single pathophysiological process independent of age.
All patients aged 2 years and above with focal epilepsy
would be expected to respond similarly to drug treatment in
terms of seizure frequency reduction, provided that dosing
led to an equivalent serum concentration–time profile.
Although there are some subtle differences in semiology of
focal seizures in the youngest age groups (i.e. paucity of
automatisms, predominance of bilateral motor signs, etc.),
these rapidly disappear with age and there is no evidence
that these seizure types are differentially responsive to first-
line therapies for focal epilepsy [11]. Consequently, it
should be possible to extrapolate efficacy data obtained in
adults with focal epilepsy to patients aged 2 years and
above. It would be inappropriate, however, to extrapolate
efficacy to patients below 2 years of age primarily because
of greater variability in aetiology and difficulties in
diagnosis.
While the natural history of epilepsies may differ
between adults and paediatrics, any differences in treat-
ment effect between adult and paediatric patients with focal
epilepsies are likely to be quantitative rather than qualita-
tive [8, 12–14]. However, this does not obviate the con-
tinued need for trials of new AEDs in paediatrics,
particularly in the case of the rarer epilepsy syndromes.
2.2 Are All Paediatric Patients the Same?
For focal epilepsies, the older age groups proposed in the
ICH E11 guidance (Table 1) [7] could in theory be merged
to create a single group that encompasses children and
adolescents aged 2–16/18 years. However, there would be
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less confidence regarding the younger age groups and
discussions with neonatologists would be required.
There is no doubt that preterm and term infants are
relatively under-investigated with minimal phase I or ran-
domised controlled trial (RCT) data. Extrapolation of
efficacy data from adults or older paediatric patients to
these groups is not possible because of differences in the
pathophysiology of the epilepsy as well as brain bio-
chemistry, brain development and drug metabolism. Drug
clearance is low in preterm and term newborn infants,
subsequently increases rapidly until around 2 years and
then declines steadily until around 12 years at which point
it is considered to have reached adult levels, such that adult
dosing can be considered for adolescents aged[12 years
[15]; this is well-illustrated by carbamazepine [16]. How-
ever, sufficient variability exists that pharmacokinetic
studies are likely to be required to support dose choices for
paediatric patients aged 2–12 years even when efficacy is
extrapolated.
In general, the behaviour of AEDs in patients aged
2 years and above is usually predictable. However, there is
a need for more robust studies in patients under 2 years
with both focal and generalised epilepsies. This is
acknowledged to be challenging, especially for patients
less than 1 month old in whom the study design would be
critical.
2.3 If a Drug is Safe in Adults, is it Safe
in Paediatrics?
There are a variety of adverse outcomes associated with
AED use, including those that are acute and dose related,
those that are chronic and exposure related, and those that
are idiosyncratic and likely to be immune mediated. For the
purposes of this article, we group them all under the term
‘safety’. Most safety issues are considered to be essentially
similar in adults and paediatrics at equivalent doses. There
is anecdotal evidence suggesting that some idiosyncratic
reactions occur at differing frequencies in adults and chil-
dren (i.e. lamotrigine-induced Stevens-Johnson syndrome),
but this may simply reflect differences in drug disposition
and in systemic exposure to the drugs or their reactive
metabolites. Those aside, it is possible, with appropriate
caution, to extrapolate most adult safety data to paediatric
patients aged 2 years and above.
Important safety issues that are specific to paediatrics
include effects on growth and on pubertal, motor, speech
and language, and cognitive development. These paediatric
safety signals cannot be reliably identified from an adult
population. Effects on learning and on social and educa-
tional development are also important, and in paediatric
patients with severe epilepsies it may be difficult to dis-
tinguish the influence of the epilepsy and its underlying
aetiology from the effects of the medications used to treat
it. Nevertheless, improvements in attention, memory,
cognition and behaviour can be observed during AED
withdrawal in paediatric patients with challenging epilepsy,
suggesting a strong influence of drug treatment.
Seizure aggravation is another important safety issue,
particularly in rare idiopathic focal epilepsies that are
typically diagnosed in childhood only. Standard treatments
can occasionally exacerbate seizures in these children but
their low prevalence in the focal epilepsy population means
that they might evade detection in controlled trials of short
duration. Inclusion of EEG follow-up in the phase II and III
trial protocols for paediatric participants would improve
detection of these paradoxical effects.
2.4 When is it Reasonable to Use Therapies
in Paediatrics that are Licensed Only
for Adults?
The decision regarding when it is reasonable to use drugs
in paediatrics that are licensed only for use in adults would
depend on the clinical situation, with a risk–benefit trade-
off determining the acceptability of off-label prescribing.
When prescribing off-label in paediatrics, a drug will often
be tried initially in adolescents before then being used in
younger patients.
In this situation there would likely be greater confidence
to enter patients in clinical trials rather than prescribe an
AED off-label, particularly because of the detailed moni-
toring performed within a trial. There is a clear need for
paediatric RCTs to be conducted earlier than at present and
in parallel or in conjunction with adult trials. This would
incentivise the recruitment of children into trials since
accrual can be challenging when a trial treatment licensed
in adults is available off-label in children. Improving
enrolment will improve the quality of paediatric RCTs
since inadequate accrual currently obliges many trialists to
recruit from small, inexperienced centres, increasing
patient heterogeneity and the risk of internal biases. Earlier
paediatric RCTs would also widen participation in trials to
include children with refractory epilepsy who are often
excluded from new drug studies on the basis that they have
Table 1 Age groups suggested by the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use (ICH) E11 guidance document [7]
Age group Age range
Preterm newborn infants
Term newborn infants 0–27 days
Infants and toddlers 28 days to 23 months
Children 2–11 years
Adolescents 12–16/18 years (dependent on region)
Clinical Drug Development in Epilepsy Revisited 1013
already been prescribed the drug off-label after failing all
other licensed medicines.
It is important to acknowledge that there may be pae-
diatric-specific issues for any RCTs undertaken in the
idiopathic focal epilepsies of childhood and particularly
benign partial epilepsy with centro-temporal spikes
(BECTS) and benign epilepsy of childhood with occipital
paroxysms (BECOP; Panayiotopoulos syndrome). The
natural history of BECTS (and probably BECOP) is such
that a spontaneous remission may occur any time, includ-
ing soon after its onset or diagnosis. Consequently, any
apparent efficacy of a drug in RCT participants with
BECTS or BECOP may be due to the drug itself or to the
natural history of the syndrome. This might risk assay
sensitivity in a non-inferiority trial but would be of less
concern if the trial was designed to detect differences and
found them.
2.5 Can we Extrapolate Efficacy Data
from Adjunctive Therapy to Monotherapy?
Extensive trial data and clinical experience with existing
AEDs has failed to find any instance where a drug behaves
differently in terms of its spectrum of efficacy and adverse
effects when administered alone or as adjunctive therapy,
except in circumstances where drug interactions might be
expected. Consequently, it would be reasonable to extrap-
olate efficacy data from adjunctive trials to inform the use
of an AED as monotherapy. Mintzer et al. [17] state that
the need for separate monotherapy and adjunctive therapy
licenses in epilepsy is ‘‘unnecessarily restrictive’’ and that
AEDs should be approved for specific seizure types or
epilepsy syndromes only.
3 An Alternative Paradigm for Developing
Medicines for Focal Epilepsies
This section outlines our proposal for the future clinical
development of drugs for focal epilepsies. This proposal
uses a partial extrapolation of adult efficacy data, gener-
ating only supportive efficacy data in children aged 2 years
and above, and a limited extrapolation of adult safety data
to justify joint phase II and III studies recruiting adult and
paediatric patients aged 2 years and above.
3.1 Phase I Trials
The primary purpose of phase I trials remains the identi-
fication of a safe range of doses of a new compound to be
used in the subsequent clinical development programme.
Such studies should continue to be undertaken in healthy
male adults only in an effort to reduce variability, limit
confounding influences and minimise the likelihood of
unexpected adverse events.
3.2 Phase IIa and IIb Trials
The primary purpose of phase IIa and IIb trials remains
determination of the effective dose range and a preliminary
assessment of safety and efficacy. Trials should be ran-
domised, placebo-controlled, adjunctive therapy studies
following current guidelines for adjunctive trials but now
recruiting patients with focal epilepsy aged 2 years and
above, obviating the current requirement for a separate
development programme in paediatrics. Using partial
extrapolation of adult efficacy data, power calculations
should be based on the entire study population but the final
analysis should be stratified by age. Long-term extension
will allow provisional assessment of safety in adults, pae-
diatrics or both. There would not be a requirement to
complete the long-term extension before progressing to
phase III. Pharmacokinetic investigations will reveal the
dose–concentration relationship in adults, paediatrics or
both. Wherever possible, pharmacokinetic data should be
analysed using population pharmacokinetic models to
accommodate sparse sampling schedules. Inclusion of
mandatory EEG follow-up for paediatric participants
would allow detection of seizure aggravation.
3.3 Phase III Trials
The primary purpose of phase III trials remains the iden-
tification of efficacy in comparison to placebo. Traditional
approaches are appropriate; i.e. randomised and placebo-
controlled trials of adjunctive therapy. Efficient adaptive
[18] and/or Bayesian [19] strategies to the design and
analysis of trials should be considered if appropriate.
Studies should again recruit patients with focal epilepsy
aged 2 years and above and should be powered to detect
treatment effects based on the total sample size accumu-
lated across adults and paediatrics but should also include
the potential for a stratified analysis. Minimum sample
sizes in each age group might be prespecified to ensure that
reliable (but not necessarily definitive) conclusions can be
drawn from the paediatric data. If a significant treatment
effect was demonstrated in adults but not in paediatric
patients and the differences could be attributed to sample
size alone, then the treatment would still be acceptable for
paediatric use provided there were no qualitative differ-
ences in the effects between adults and paediatric patients.
Long-term extension will allow additional open-label
assessment of safety and efficacy in adults, paediatrics or
both. Further pharmacokinetic investigations and EEG
follow-up may be required, particularly in paediatric
patients.
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3.4 Licensing of Treatments
Under this new paradigm, since all pivotal trials would be
conducted in both paediatrics and adults, licensing should
also apply to all age groups from 2 years upwards.
Licenses should be granted for a general indication of
‘focal epilepsy’, allowing their discretionary use as either
adjunctive therapy or monotherapy unless there is reason to
impose a restriction. Approval for paediatric use (2–16/
18 years) should be conditional on a prospective, time-
limited commitment to collect safety data from paediatric
patients on growth and on neurological and cognitive
development. Ideally, these neurodevelopmental safety
data would be collected within a randomised, placebo-
controlled design, but this is likely to pose significant
logistical issues. Consequently, it would be appropriate and
sufficient to collate multiple audit and observational data.
This is a pragmatic solution since the challenges of
deducing unbiased estimates of causal effects from obser-
vational data in the presence of unmeasured confounders
are well-documented [20]. Caution should also be exer-
cised to prevent or at least monitor the use of drugs
licensed for ‘focal epilepsy’ in more complex epilepsies
that express multiple seizure types; the focal component
may be improved but other seizure types may be simulta-
neously exacerbated.
The approach proposed here has been used to develop
rufinamide for Lennox-Gastaut syndrome [21, 22]. How-
ever, this was a syndrome-specific development pro-
gramme for a relatively rare epilepsy. The paradigm
suggested here is a more general framework for common
epilepsies which considers other factors such as adjunctive
therapy and monotherapy. It dispenses with the need for a
separate paediatric development programme and a separate
monotherapy trial programme, neither of which have clear
additional benefits in focal epilepsies.
3.5 Shift in Research Culture
The adoption of this proposed framework for drug devel-
opment in epilepsy may require a shift in culture. A net-
work of specialist paediatric epilepsy centres is needed to
coordinate recruitment of patients into regulatory trials of
AEDs, in a manner similar to the common practice in
paediatric oncology. Rather than specialists making third-
or fourth-line treatment decisions for paediatric patients,
they should randomise those patients into trials; this would
advance knowledge much more rapidly. Those anxious
about undertaking combined trials in adults and paediatrics
should consider the SANAD (Standard and New
Antiepileptic Drugs) studies, which remain the largest ever
randomised trials in epilepsy and which successfully
recruited across the age spectrum from 5 years upwards
[23, 24]. Fears over inclusion of paediatric patients in
randomised trials should be tempered with examples of
paediatric epilepsy studies that have successfully hit their
recruitment targets in a timely manner [25–28] and with
evidence regarding parents’ opinions on enrolment of their
children into RCTs [29]. Finally, improved interaction with
neonatologists would help to ensure that treatments for
epileptic seizures in the very youngest age groups do not
lag behind those for others.
4 Conclusions
This proposed paradigm for drug development in epilepsy
has many potential benefits for epilepsy and epilepsy
research; paediatric patients gain from immediate access to
new treatments, trialists have access to a broader patient
population, fewer trials and less restrictive licensing will
incentivise sponsors, broaden their market and re-invigo-
rate drug development for epilepsy, and research and
development savings can be expected to have knock-on
effects for medication costs and the allocation of healthcare
resources.
It is acknowledged that there are potential dangers in a
condensed AED trial programme because of the volume of
data and number of patient exposures. There may also be
additional complexities to conducting trials in adults and
children if, for example, drug formulations or dosing rules
vary across age groups, although several successful trials
show these barriers are not insurmountable [28]. The next
step in this process is to seek the opinion of patients, par-
ents and guardians, regulatory authorities and sponsors on
the risks, benefits and feasibility of the proposed paradigm.
This article is written within the context of growing
international interest in the place of extrapolation in the
development of medicines for paediatric epilepsies. Fol-
lowing the publication of robust evidence demonstrating
that efficacy in RCTs recruiting adults with focal epilepsies
can similarly predict efficacy in children [12], a US con-
sortium from academia, industry, the FDA and the Epi-
lepsy Foundation was formed to further explore and
develop this concept. The Pediatric Epilepsy Academic
Consortium for Extrapolation (PEACE) has since drafted a
white paper establishing disease similarity in adults and
children. Additional pharmacometric analyses are also
currently underway at the FDA to further evaluate phar-
macokinetic and pharmacodynamic properties of AEDs.
The PEACE group has shown that ever since a 1994
National Institute of Neurological Disorders and Stroke
(NINDS) workshop agreed that most children with focal
epilepsies would respond to a drug that was also efficacious
in adults with focal epilepsies [30], further clinical and
basic science data have served to strengthen this viewpoint.
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After excluding children below 4 years and those with
focal seizures associated with epileptic encephalopathy,
such as Lennox-Gastaut syndrome, the pathophysiology of
focal epilepsies is similar in children and adults. The
PEACE white paper will therefore recommend that AEDs
shown to be effective in adults with focal epilepsies should
be considered as effective in children aged 4 years and
above. This proposal will be limited to efficacy, noting that
safety and pharmacokinetics may not necessarily be
extrapolated.
There are subtle differences in the proposals being
developed by the PEACE group in the USA and those
presented here. Nonetheless, it is encouraging to note that
these discussions are taking place, simultaneously and
independently, on both sides of the Atlantic. Extrapolation
is clearly high on the agenda of those interested in expe-
diting the development of new medications for epilepsy.
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